<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systematic clinical assessment and careful monitoring of patients with <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> (HCM) can be used to identify a cohort of patients that benefit from medical intervention and almost certainly improve long-term outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>One of the major limitations of the current approach is a lack of predictive power of individual risk factors, which means that many patients receive therapy </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this review is to highlight other aspects of the disease, assessed using old and new medical technologies, that appear to provide new prognostic information </plain></SENT>
<SENT sid="3" pm="."><plain>The hope for the future is that their incorporation in new risk algorithms will improve treatment for <z:hpo ids='HP_0000001'>all</z:hpo> HCM patients with the disease, irrespective of their vulnerability to adverse complications </plain></SENT>
</text></document>